Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
PathologyWatch
AddedFeb 27, 2023
UpdatedJun 18, 2026
PathologyWatch

PathologyWatch

Venture

An intuitive and easy-to-implement digital pathology solution for dermatologists and labs.

Founded
2017
Overview
Analysis
Compare
Fundraising
Employees

PathologyWatch is a computational pathology platform founded in 2017 by Daniel Lambert. It offers an intuitive digital pathology solution for dermatologists and labs, focusing on detecting and characterizing cancers from biopsy samples. The platform digitizes histologic slides and distributes images to a network of academic-level dermatopathologists, providing instant remote access to expert consultation and digital tools, enhancing hospital efficiency in diagnosing skin cancer.

PathologyWatch has significantly impacted the medical field by streamlining the diagnostic process for skin cancer, enabling faster and more accurate diagnoses. Its network of skilled experts and advanced digital tools has improved the efficiency and effectiveness of dermatopathology services, contributing to better patient outcomes.

PathologyWatch - Similar Companies

PathAI logo

PathAI

4D Path logo

4D Path

4dpath.com

Enlitic logo

Enlitic

enlitic.com

Viz.ai logo

Viz.ai

viz.ai

Artera logo

Artera

artera.io

Nucleai logo

Nucleai

Proscia logo

Proscia

proscia.com

Paige logo

Paige

paige.ai

Glass Health logo

Glass Health

glass.health

Pathology Watch logo

Pathology Watch

pathologywatch.com

Pathware logo

Pathware

pathware.com

HistoWiz logo

HistoWiz

histowiz.com

Pramana logo

Pramana

pramana.ai

Digipath logo

Digipath

Histolix logo

Histolix

histolix.com

PathologyWatch - Quick Facts

Who are PathologyWatch's competitors?

Companies similar to PathologyWatch include PathAI, 4D Path, Enlitic and Viz.ai.

When was PathologyWatch founded?

PathologyWatch was founded in 2017.

When was PathologyWatch's last funding round?

PathologyWatch's most recent funding round was for $22.3M (USD) in March 2023.

How much has PathologyWatch raised to-date?

As of Mar 6, 2023, PathologyWatch has raised a total of $54.6M (USD).

How many employees does PathologyWatch have?

PathologyWatch has 48 employees as of Mar 8, 2023.

PathologyWatch - Classification

Geographic Exposure
  • Global
Main Product
  • Pathology Software